Financial News

Financial Report: Alexion

Soliris revenues up 17% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Alexion   1Q Revenues: $701 million (+17%) 1Q Earnings: $92.2 million (+1%) Comments: Soliris saw steady increase of new patients in the U.S., Europe and Japan with sales of $665 million, up 17%. Strensiq for Hypophosphatasia launched with $33 million sales in initial countries. U.S. launch for Kanuma (sebelipase alfa) for Lysosomal Acid Lipase (LAL) deficiency is under way....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters